Posted by Michael Wonder on 08 Sep 2023
Inovio announces US FDA breakthrough therapy designation granted for INO-3107 for the treatment of recurrent respiratory papillomatosis
7 September 2023 - Designation based on clinical evidence indicating INO-3107 may demonstrate substantial improvement over existing therapies.
Inovio today announced that the US FDA has granted breakthrough therapy designation for INO-3107 as a potential treatment for patients with recurrent respiratory papillomatosis.
